Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
The Journal of Experimental Medicine|July 1, 1976
Isolation and immunologic characterization of a human. B-lymphocyte-specific, cell surface antigenR E Humphreys, J M McCune, L Chess, et al.
Frontiers in Molecular Biosciences|May 25, 2023
Overexpression of IκB⍺ modulates NF-κB activation of inflammatory target gene expressionPolly Downton, James S Bagnall, Hazel England, et al.
Journal of the National Cancer Institute|August 1, 1979
Distribution of Lyb-4.1 and other membrane antigens on murine lymphoid tumorsR C Howe, R S Nelson, K M Rogan, et al.
Vaccine|January 1, 1992
Biophysical mechanism of the scavenger site near T cell-presented epitopesS Lu, V E Reyes, C M Bositis, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugsKelly M Mahar Doan, Joan E Humphreys, Lindsey O Webster, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 12, 2004
A phase II study of G17DT in gastric carcinomaA D Gilliam, S A Watson, M Henwood, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 25, 2008
The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactionsJoseph W Polli, Joan E Humphreys, Kelly A Harmon, et al.
Cancer Immunology, Immunotherapy : CII|September 9, 2006
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumorsNectaria N Sotiriadou, Nikoletta L Kallinteris, Angelos D Gritzapis, et al.
Cancer Treatment Reviews|April 3, 2004
Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidationGilda G Hillman, Nikoletta L Kallinteris, Xueqing Lu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 8, 2012
In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitorMelinda J Reese, Paul M Savina, Grant T Generaux, et al.
Pageof 19